Sign in

CIK 0001799788 · Non-accelerated filer<br>Smaller reporting company

Greenwich LifeSciences, Inc.

Sign in to watch
Ticker
GLSI
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
205473709
Phone
203-434-3290
Business address
3992 BLUEBONNET DR, BUILDING 14, STAFFORD, TX, 77477
  1. 4 Open-market buy VP Clinical Reg Affairs bought 250 shares at $11.22 ($2,805)
  2. 4 Open-market buy CEO and CFO bought 7,000 shares at $11.10 ($77,700)
  3. 4 Open-market buy CEO and CFO bought 2,000 shares at $11.12 ($22,240)
  4. 4 Open-market buy VP Clinical Reg Affairs bought 1,000 shares at $11.87 ($11,870)
  5. 4 Open-market buy CEO and CFO bought 5,000 shares at $12.42 ($62,100)
  6. 4 Open-market buy VP Clinical Reg Affairs bought 250 shares at $12.71 ($3,178)
  7. 4 Open-market buy CEO and CFO bought 1,000 shares at $12.12 ($12,120)
  8. 4 Open-market buy VP Clinical Reg Affairs bought 250 shares at $15.40 ($3,849)
  9. 4 Open-market buy CEO and CFO bought 600 shares at $16.53 ($9,918)
  10. 4 Open-market buy CEO and CFO bought 1,000 shares at $18.68 ($18,680)
  11. 4 Open-market buy VP Clinical Reg Affairs bought 250 shares at $20.84 ($5,210)
  12. 4 Open-market buy CEO and CFO bought 2,000 shares at $19.35 ($38,700)
  13. 4 Open-market buy VP Clinical Reg Affairs bought 250 shares at $19.20 ($4,800)
  14. 4 Open-market buy CEO and CFO bought 1,500 shares at $17.37 ($26,055)
  15. 4 Open-market buy VP Clinical Reg Affairs bought 250 shares at $16.50 ($4,125)
  16. 4 Open-market buy CEO and CFO bought 1,500 shares at $15.18 ($22,770)
  17. 4 Open-market buy CEO and CFO bought 4,000 shares at $15.19 ($60,760)
  18. 4 Open-market buy CEO and CFO bought 1,000 shares at $13.01 ($13,010)
  19. 4 Open-market buy VP Clinical Reg Affairs bought 250 shares at $12.94 ($3,235)
  20. 4 Open-market buy CEO and CFO bought 2,000 shares at $13.11 ($26,220)

Page 4 of 8 · 146 filings